Before taking oral deca 200 suspension Shake well and immediately measure out the required amount of suspension. The required dose (ml) are drawn from the bottle using the supplied syringe. When using a 10 ml syringe (provided with a 250 ml bottle – for adults and older children) amount of the slurry should be rounded up to 0.5 ml. When using a 1 ml syringe (provided with the bottle of 100 ml – for younger children), the number of suspensions should be rounded up to 0.1 ml. After each use, should be tightly closed vial and wipe the gun with a clean dry cloth. The suspension can be taken directly from the syringe or diluted with a little water before taking. Open the vial to store no more than 7 weeks.
Oral suspension and film-coated tablets are used interchangeably at equivalent doses.
most frequently reported the following adverse reactions:. Drowsiness, headache, dizziness, diplopia, nausea, vomiting, fatigue (more than 10% of patients)
In clinical studies it was shown that adverse effects are usually mild or moderately expressed, . are transient and occur mainly at the beginning of therapy
The following data summarize the information about adverse events reported in clinical trials, as well as data on the safety profile of the drug obtained in the course of its use in clinical practice.
Criteria for assessing the incidence of adverse events: . From the hematopoietic system: sometimes – leukopenia; very rarely – the suppression of bone marrow hematopoiesis, agranulocytosis, aplastic anemia, neutropenia, pancytopenia, thrombocytopenia. Immune system: very rarely – hypersensitivity accompanied by fever and rash (including multiple organ disorders).
With the development of hypersensitivity reactions may result in circulatory and lymphatic systems (eosinophilia, thrombocytopenia, lymphadenopathy, splenomegaly), muscles and joints (myalgia, swelling in the joints, arthralgia), nervous system (encephalopathy), kidney (proteinuria, interstitial nephritis, renal failure ), pulmonary deca 200 (dyspnea, pulmonary edema, bronchospasm, interstitial inflammation), abnormal liver function, angioedema, anaphylactic reactions. Metabolic and nutrition disorders: often – hyponatremia; very rarely – hyponatremia, leading to the development of signs and symptoms, such as seizures, confusion, decreased level of consciousness, encephalopathy, visual disturbances (including “blurred” vision), nausea, vomiting, folic acid deficiency; very rarely – hypothyroidism. On the part of the central nervous system: very often – drowsiness, headache, dizziness; often – ataxia, tremor, nystagmus, disturbance of attention, amnesia; confusion, depression, apathy, agitation, emotional lability. From the senses : very often – diplopia;often – visual impairment, “blurred” vision, vertigo.
On the part of the cardiovascular system: very rarely – arrhythmias, hypertension. On the part of the gastrointestinal tract: often – nausea, vomiting; often – diarrhea, constipation, stomach pain; very rarely – pancreatitis and / or an increase in lipase and / or amylase. Liver and zhepchevyvodyaschih ways: very rarely – hepatitis. Dermatological reactions: often – a rash, alopecia, acne; sometimes – urticaria; very rarely – angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), erythema multiforme. On the part of the connective tissue: very rare deca 200 – systemic lupus erythematosus. Other: very often – feeling tired; often – asthenia. Disorders laboratory parameters: sometimes – increased activity of liver enzymes, increased concentration of alkaline phosphatase in the blood. In very rare cases during treatment with Trileptal may develop clinically significant hyponatremia . With a frequency of> 1% – <10% (often) had ataxia, irritability, vomiting, lethargy, fatigue, nystagmus, tremor, decreased appetite, increase in the concentration of uric acid in the blood.